

# TABLE OF CONTENTS

<b>Chronic Conditions and Public Health I</b> . . . . .	1	<b>Pregnancy Wellness and Antenatal Care</b> . . . . .	81
Chronic Conditions and Public Health I Panel . . . . .	3	<i>By Kylie N. Barnes, Pharm.D., BCPS; and Lauren D. Leader, Pharm.D., BCPS</i>	
<b>Drug Interactions: Scientific and Clinical Principles</b> . . . . .	7	Introduction . . . . .	81
<i>By Michael Gabay, Pharm.D., JD, FCCP, BCPS; and Samantha H. Spencer, Pharm.D., BCPS</i>		Managing Chronic Conditions During Pregnancy . . . . .	83
Introduction . . . . .	7	Risk Reduction Strategies and Preconception Planning . . . . .	94
Mechanisms of Drug Interactions . . . . .	9	Conclusion . . . . .	96
Prevention of Drug Interactions . . . . .	12	References . . . . .	96
Drug Interaction Resources . . . . .	15	Self-Assessment Questions . . . . .	101
Conclusion . . . . .	24	<b>Routine Adult Immunizations and COVID-19 Vaccines</b> . . . . .	105
References . . . . .	24	<i>By Elias B. Chahine, Pharm.D., FCCP, FASCP, FFSHP, BCPS, BCIDP; and Allana J. Sucher, Pharm.D., BCPS, BCIDP</i>	
Self-Assessment Questions . . . . .	26	Vaccine-Preventable Diseases in the Era of a Pandemic . . . . .	105
<b>Monitoring of Adverse Drug Reactions and REMS</b> . . . . .	31	Vaccine Types . . . . .	106
<i>By Karen L. Kier, Ph.D., FASHP, FCCP, BCPS, BCACP</i>		Influenza . . . . .	119
Introduction . . . . .	31	Invasive Pneumococcal Disease . . . . .	121
Regulations and Programs . . . . .	34	Meningococcal Disease . . . . .	122
Pharmacovigilance/Data Mining . . . . .	36	Herpes Zoster . . . . .	124
Assessment of ADRs . . . . .	36	Tetanus, Diphtheria, and Pertussis . . . . .	125
REMS Requirements . . . . .	45	Hepatitis A . . . . .	126
REMS Monitoring and Quality Assurance . . . . .	46	Hepatitis B . . . . .	127
Conclusion . . . . .	47	Coronavirus Disease 2019 . . . . .	128
References . . . . .	48	Role of the Pharmacist in Addressing Pseudoscience and Vaccine Hesitancy . . . . .	129
Self-Assessment Questions . . . . .	51	Conclusion . . . . .	130
<b>Chronic Conditions and Public Health II</b> . . . . .	55	References . . . . .	130
Chronic Conditions and Public Health II Panel . . . . .	57	Self-Assessment Questions . . . . .	134
<b>Patient Wellness, Health Screening, and Preventive Medicine</b> . . . . .	61	<b>Chronic Conditions and Public Health III</b> . . . . .	137
<i>By Melissa Lipari, Pharm.D., BCACP</i>		Chronic Conditions and Public Health III Panel . . . . .	139
Introduction . . . . .	61	<b>Interactive Case: Psoriasis</b> . . . . .	143
Wellness . . . . .	61	<i>By Timothy D. Gladwell, Pharm.D., BCPS, BCACP</i>	
Health Screening and Preventive Medicine . . . . .	62	Interactive Case: Psoriasis . . . . .	143
Patient Wellness . . . . .	64	Hyperlink to Activity . . . . .	143
Disease Prevention Screening Recommendations . . . . .	69	References . . . . .	144
Support Programs and Apps . . . . .	72	Self-Assessment Questions . . . . .	146
Conclusion . . . . .	74	<b>Interactive Case: Combination Therapies in BPH</b> . . . . .	149
References . . . . .	74	<i>By Mary Barna Bridgeman, Pharm.D., FNAP, BCPS, BCGP; and Luigi Brunetti, Pharm.D., MPH, BCPS, BCGP</i>	
Self-Assessment Questions . . . . .	77	Interactive Case: Combination Therapies in BPH . . . . .	150
		Hyperlink to Activity . . . . .	150
		References . . . . .	150
		Self-Assessment Questions . . . . .	152